Cite
HARVARD Citation
Wang, M. et al. (2022). Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for young patients (≤65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase 2 trial. Lancet oncology. 23 (3), pp. 406-415. [Online].